Navigation Links
IMMUNE Pharmaceuticals Announces Alan G. Harris MD, PhD, FRCP as Chief Medical Officer
Date:9/13/2011

NEW YORK, Sept. 13, 2011 /PRNewswire/ -- IMMUNE Pharmaceuticals, an emerging leader in the development of Antibody based Therapeutics for the treatment of inflammatory diseases and cancer, today announced the appointment of Dr. Alan Harris, M.D., Ph.D., to the position of Chief Medical Officer.  In this new position, Dr. Harris will play a pivotal  role in the development of Bertilimumab, IMMUNE's phase II ready fully human monoclonal antibody in development for Crohn's Disease and Ulcerative Colitis,  as well as  NanoMAb development candidates in oncology. NanoMAbs are next generation bio- therapeutics with targeting mAbs conjugated to drug loaded nanoparticules.

"Alan brings impressive credentials and pharmaceutical clinical  development experience to the IMMUNE team," said Dr. Daniel Teper, Founder, Chairman of the Board and Chief Executive Officer of IMMUNE Pharmaceuticals.  "We are delighted to attract someone of Alan's caliber to our growing organization.  He will be a tremendous asset and play a critical role as IMMUNE evolves into a clinical stage company."

Dr. Harris led the clinical development of Novartis' somatostatin analogue, octreotide (Sandostatin®), for the treatment of gastrointestinal tumors and endocrine diseases.  More than 20 years after its introduction, Sandostatin remains a leading therapy, with sales reaching $1.4 billion in 2010.  Dr. Harris has also held leadership positions overseeing the clinical development of small molecules and biologics as Vice President of Research at Schering Plough, Therapeutic Head of Endocrinology at Pfizer, Senior Vice President of R & D and Chief Medical Officer at NPS Pharmaceuticals.

Dr. Harris is currently Adjunct Professor in the Department of Pharmacology at NYU Medical Center in New York, and was previously Associate Professor of Medicine at UCLA Medical School and Director of the Division of Clinical Pharmacology in the Department of Medicine at Cedars-Sinai Medical Center.  He has authored over 120 peer-reviewed scientific articles.  

Dr. Harris is a fellow of the American College of Physicians and the Royal College of Physicians (UK). He received his MD from the University of Strasbourg, France and his Ph.D. in endocrinology from Erasmus University, Rotterdam, The Netherlands.  

"I am thrilled and gratified to join the IMMUNE Pharmaceuticals' Management Team to lead the clinical development of its first in class fully human monoclonal antibody antagonist of eotaxin-1, a proinflammatory chemokine, in the treatment of inflammatory bowel diseases and other conditions of great medical need. Bertilimumab is supported by a strong scientific rationale and a solid regulatory file. Phase II trials will help determine its potential as a novel treatment option," said Dr Harris.

IMMUNE Pharmaceuticals will be presenting at the Rodman & Renshaw Conference on September 13, 2011 at 3.40 pm in the Metropolitan East Room at the Waldorf Astoria, New York.

About IMMUNE Pharmaceuticals

IMMUNE Pharmaceuticals is an Israel and U.S. based biopharmaceutical company focused on the development of next generation monoclonal antibodies addressing significant unmet medical needs in the treatment of inflammatory diseases and cancer. IMMUNE Pharmaceuticals has built a robust pipeline of clinical and pre-clinical candidates based on novel targets and best-in-class antibody technologies. IMMUNE licensed worldwide rights for systemic indications of Bertilimumab from iCo Therapeutics (TSX: ICO) in June 2011, while iCo retained rights to all ophthalmic indications. iCo originally  licensed the exclusive world-wide rights to Bertilimumab in 2006 from MedImmune Limited (formerly known as Cambridge Antibody Technology Limited), the Global Biologics Unit of AstraZeneca.

For more information, visit the Company website at: www.immunepharmaceuticals.com 

Forward Looking Statements

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based IMMUNE Pharmaceuticals  current beliefs as well as assumptions made by and information currently available to IMMUNE Pharmaceuticals and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.  Due to risks and uncertainties; actual events may differ materially from current expectations. IMMUNE Pharmaceuticals disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:
Mr. Serge Goldner, Chief Financial Officer
IMMUNE Pharmaceuticals
+972505203100 serge.goldner@immunepharma.com

Ms Justyna Figiel, Media and Investor Relations
IMMUNE Pharmaceuticals
347-437-0218 justyna.figiel@immunepharma.com

Mrs. Marcy Nanus, Vice President
The Trout Group, LLC.
646-378-2927, mnanus@troutgroup.com


'/>"/>
SOURCE IMMUNE Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
3. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
4. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
5. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
6. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
7. Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
8. MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results
9. MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV
10. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
11. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Calif. , Oct. 11, 2017  BioPharmX Corporation ... scientific team that developed an innovative way to use ... of the delivery of new drugs. ... Fall Clinical Dermatology Conference will show how researchers from ... Hospital, Harvard Medical School used a suite of imaging ...
(Date:10/10/2017)... Oct. 10, 2017   West Pharmaceutical Services, Inc. ... for injectable drug administration, today shared the results of ... for improving the intradermal administration of polio vaccines. The ... Summit in May 2017 by Dr. Ondrej Mach ... World Health Organization (WHO), and recently published in the ...
(Date:10/4/2017)... , Oct. 4, 2017 ... single-use, self-contained, illuminating medical devices, today announced regulatory ... Health Surveillance Agency (or Agência Nacional de Vigilância ... first single-use, cordless surgical retractor with integrated LED ... optimal access, illumination and exposure of a tissue ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... Lori R. Somekh, founder of the Law Office ... of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our office ... forum to network with elder law attorneys nationwide,” said Somekh. , ElderCounsel ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
Breaking Medicine News(10 mins):